Last reviewed · How we verify
adalimumab, plus prednisone
Adalimumab blocks tumor necrosis factor-alpha (TNF-α) to reduce inflammation, while prednisone provides additional immunosuppression via glucocorticoid receptor activation.
Adalimumab blocks tumor necrosis factor-alpha (TNF-α) to reduce inflammation, while prednisone provides additional immunosuppression via glucocorticoid receptor activation. Used for Rheumatoid arthritis, Inflammatory bowel disease (Crohn's disease, ulcerative colitis), Ankylosing spondylitis.
At a glance
| Generic name | adalimumab, plus prednisone |
|---|---|
| Also known as | humira (adalimumab), deltacortene (prednisone) |
| Sponsor | Fondazione IRCCS Policlinico San Matteo di Pavia |
| Drug class | TNF-α inhibitor (adalimumab) + corticosteroid (prednisone) |
| Target | TNF-α receptor (adalimumab); glucocorticoid receptor (prednisone) |
| Modality | Small molecule |
| Therapeutic area | Immunology / Rheumatology |
| Phase | FDA-approved |
Mechanism of action
Adalimumab is a monoclonal antibody that binds TNF-α and prevents its interaction with TNF receptors, thereby suppressing inflammatory cytokine signaling. Prednisone is a corticosteroid that broadly suppresses immune cell activation and inflammatory mediator production. Together, this combination provides dual anti-inflammatory and immunosuppressive effects for managing severe inflammatory or autoimmune conditions.
Approved indications
- Rheumatoid arthritis
- Inflammatory bowel disease (Crohn's disease, ulcerative colitis)
- Ankylosing spondylitis
- Psoriatic arthritis
- Other TNF-α-responsive autoimmune or inflammatory conditions
Common side effects
- Infection (including serious infections)
- Injection site reactions
- Headache
- Nausea
- Immunosuppression-related complications
- Corticosteroid-related effects (weight gain, hyperglycemia, osteoporosis)
Key clinical trials
- Early Adalimumab Induction for Immune Checkpoint Inhibitor Associated Inflammatory Arthritis (PHASE2)
- Determination of the Optimal Treatment Target in Ulcerative Colitis (PHASE4)
- A Randomized, Controlled, Open-label, Multicenter Clinical Trial Comparing the Efficacy and Safety of a Precision Treatment Regimen Based on Clinical-molecular Phenotypes with a Conventional Treatment Regimen in the Treatment of Patients with Active Takayasu's Arteritis (PHASE4)
- IL-7 and IL-7R Expression in RA Patients With Active vs. Inactive Disease Treated With DMARD or CIMZIA (PHASE4)
- Impact of Medical Treatment on Sexual Function in Patients With Crohn's Disease
- Corticosteroid Combining Noncorticosteroid Systemic Immunomodulatory Therapy in VKH
- Efficacy and Safety of Adalimumab Plus Medium Dose Oral Glucocorticosteroid for Refractory Behçet's Uveitis (PHASE4)
- Efficacy and Safety of Adalimumab in Subjects With Inactive Uveitis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: